Insurance Journal | September 1, 2022
A long-awaited review of prescription opioid medications, including their risks and contribution to the U.S. overdose epidemic, is still underway at the Food and Drug Administration, the agency’s commissioner said Tuesday. Dr. Robert Califf wrote in a blog entry that …